INDIA – Baxter India, a global leader in dialysis care, has announced a new education campaign called “Choose Freedom” to raise patient awareness of peritoneal dialysis (PD) therapy, reiterating its support for end stage kidney disease (ESKD) patients.
The campaign aligns with Baxter’s commitment to make PD the initial dialysis therapy of choice by providing smarter patient-centric solutions that enable healthcare professionals to give their patients the best possible care for chronic kidney disease (CKD).
Nearly 850 million people suffer from chronic kidney disease in the world. The disease is a growing epidemic and a rising global public health concern.
CKD is a progressive disease characterized by gradual loss of kidney function and if left untreated, the debilitating condition can progress to kidney failure, also known as end stage kidney disease, which requires dialysis.
Peritoneal dialysis therapy is an option for at-home dialysis that carries a decreased risk of infection and can be handled independently by the patient after receiving the necessary training, ultimately empowering patients to achieve their lifestyle goals.
The “Choose Freedom” campaign focuses on efforts to spread awareness, increase education, and improve the understanding of peritoneal dialysis (PD) therapy, particularly the importance of timely dialysis treatment.
In a press release, Baxter said: “The campaign will help achieve the quadruple aim of better clinical outcomes, allowing patients to maintain their lifestyle and independence, and improving health care professionals’ experiences.”
The Gurugram-based company emphasized the need for urgent action to address the growing CKD health crisis to ensure those affected by the disease are empowered with the right resources to make informed decisions about treatment options.
“The Choose Freedom campaign provides patients with the knowledge and confidence to have meaningful conversations about peritoneal dialysis and emphasises the potential positive impact of shared decision-making,” stated Baxter.
The manufacturer pointed out that the initiative takes a collaborative approach in which patients and their families work with healthcare professionals to choose the dialysis option that works best for their clinical condition, social circumstances, and lifestyle.
According to the company’s statement, dialysis is the most common form of treatment for CKD patients and it involves the removal of waste and excess fluid from the blood when the kidneys are no longer able to fulfil that function well.
Baxter underscored that peritoneal dialysis may offer several clinical, quality-of-life, and economic benefits for patients and providers.
PD therapy enables healthcare professionals to offer potentially better clinical outcomes as well as empowers patients to achieve their lifestyle goals and live well while on dialysis.
In addition, patients with chronic kidney disease were advised to discuss all degrees of decreased kidney function with nephrologists in order to make an informed decision about their course of treatment.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
